FDA Peptide Tracker

Semaglutide: live FDA regulatory status

GLP-1 weight-loss · GLP-1

The two signals

Plain-English verdict: green.

Regulatory status: 503A / shortage-exception pathway.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Available

What Semaglutide is

A GLP-1 medicine that lowers appetite and blood sugar, the most-studied molecule in the whole category.

This is the real, trial-grade end of 'peptides.' Large randomized human trials, FDA-approved branded versions, and a compounded route under clinician care. We talk about the path, not just the molecule.

Semaglutide is where the hype finally meets the evidence. The job we do isn't selling the molecule, it's the path around it: the dose that fits you, the muscle you keep, and what happens when you graduate off.

Why it sits in this category

Semaglutide is tracked under GLP-1. Its regulatory status is 503A / shortage-exception pathway — a separate signal from whether you can actually get it today. We never collapse the two.

A GLP-1 receptor agonist that slows gastric emptying and signals satiety, reducing appetite and improving glycemic control.

What it does — and what it does not do

What it does: Reduces appetite and supports meaningful weight loss and blood-sugar control, with the strongest human evidence in the category.

What it does not do: It is not a cosmetic shortcut and not risk-free; compounded forms are not FDA-approved, and we make no guaranteed-loss claims.

What would have to change

Next milestone on the regulatory path: 503B comments close — Jun 29, 2026. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Evidence grade A — Strong human evidence. multiple large randomized controlled trials in humans (STEP program) See our grading methodology for what each grade means.

What we still don't know: Long-term outcomes of compounded (vs. branded) formulations are less characterized; durability after stopping depends heavily on the habits built alongside it.

Regulatory timeline

Semaglutide: common questions

Is compounded Semaglutide legal in 2026?
It is available today through the 503A shortage-exception pathway, on a valid prescription from a licensed clinician. That pathway is narrowing: the FDA has proposed permanently excluding GLP-1 bulks from 503B, and comments closed June 29, 2026. Compounded medications are prepared for an individual patient and are not FDA-approved.
Can I get Semaglutide right now?
Yes, if a US-licensed clinician reviews your information and decides it is appropriate. We make no promise about how long supply lasts — the regulatory pathway is actively winding down, and we would rather say that than imply it is permanent.
Is compounded Semaglutide the same as the brand drug?
No. Compounded Semaglutide is prepared for an individual patient and is not FDA-approved. The FDA-approved brand products have been reviewed for safety and efficacy; a compounded preparation has not.
What happens next for Semaglutide?
The 503B exclusion comment period closed June 29, 2026. The FDA's next move on that proposal is the milestone to watch, and it could change availability.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.